Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study.
Adult
Aged
Bacteria
/ classification
Breast Diseases
/ microbiology
Breast Neoplasms
/ microbiology
Case-Control Studies
DNA, Bacterial
/ genetics
DNA, Ribosomal
/ genetics
Feces
/ microbiology
Female
Gastrointestinal Microbiome
Ghana
High-Throughput Nucleotide Sequencing
Humans
Logistic Models
Middle Aged
Odds Ratio
Phylogeny
RNA, Ribosomal, 16S
/ genetics
Sequence Analysis, DNA
/ methods
Young Adult
breast cancer
microbiome
nonmalignant breast diseases
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
revised:
15
12
2020
received:
03
08
2020
accepted:
21
12
2020
pubmed:
19
1
2021
medline:
14
9
2021
entrez:
18
1
2021
Statut:
ppublish
Résumé
The gut microbiota may play a role in breast cancer etiology by regulating hormonal, metabolic and immunologic pathways. We investigated associations of fecal bacteria with breast cancer and nonmalignant breast disease in a case-control study conducted in Ghana, a country with rising breast cancer incidence and mortality. To do this, we sequenced the V4 region of the 16S rRNA gene to characterize bacteria in fecal samples collected at the time of breast biopsy (N = 379 breast cancer cases, N = 102 nonmalignant breast disease cases, N = 414 population-based controls). We estimated associations of alpha diversity (observed amplicon sequence variants [ASVs], Shannon index, and Faith's phylogenetic diversity), beta diversity (Bray-Curtis and unweighted/weighted UniFrac distance), and the presence and relative abundance of select taxa with breast cancer and nonmalignant breast disease using multivariable unconditional polytomous logistic regression. All alpha diversity metrics were strongly, inversely associated with odds of breast cancer and for those in the highest relative to lowest tertile of observed ASVs, the odds ratio (95% confidence interval) was 0.21 (0.13-0.36; P
Identifiants
pubmed: 33460452
doi: 10.1002/ijc.33473
pmc: PMC8386185
mid: NIHMS1734316
doi:
Substances chimiques
DNA, Bacterial
0
DNA, Ribosomal
0
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2712-2723Subventions
Organisme : Intramural NIH HHS
ID : ZIA CP010126
Pays : United States
Informations de copyright
© 2021 UICC.
Références
J Natl Cancer Inst. 2015 Jun 01;107(8):
pubmed: 26032724
Nat Biotechnol. 2017 Nov;35(11):1077-1086
pubmed: 28967885
Cancer Causes Control. 2020 Nov;31(11):1027-1038
pubmed: 32844256
Genome Med. 2016 Apr 21;8(1):46
pubmed: 27102537
Am J Hum Genet. 2015 May 7;96(5):797-807
pubmed: 25957468
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Nature. 2012 Sep 13;489(7415):231-41
pubmed: 22972296
Breast Cancer Res. 2017 May 1;19(1):52
pubmed: 28460643
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Am J Epidemiol. 2018 Apr 1;187(4):705-716
pubmed: 28641369
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 28376198
Am J Epidemiol. 2019 Sep 1;188(9):1646-1654
pubmed: 31107507
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Breast Cancer Res Treat. 2017 Feb;162(1):105-114
pubmed: 28025716
Cancer Causes Control. 2010 Jun;21(6):821-8
pubmed: 20084540
J Natl Cancer Inst. 2016 Apr 22;108(8):
pubmed: 27107051
Breast Cancer Res. 2019 Mar 1;21(1):35
pubmed: 30823902
Carcinogenesis. 2018 Apr 5;39(4):571-579
pubmed: 29324997
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
Cell Host Microbe. 2019 Nov 13;26(5):666-679.e7
pubmed: 31607556
JNCI Cancer Spectr. 2018 Dec 10;2(3):pky051
pubmed: 31360866
Pestic Biochem Physiol. 2019 Sep;159:68-79
pubmed: 31400786
J Natl Cancer Inst. 2017 Oct 1;109(10):
pubmed: 28376199
ISME J. 2012 Aug;6(8):1621-4
pubmed: 22402401
Microbiome. 2018 Aug 6;6(1):136
pubmed: 30081953
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2889-97
pubmed: 16365006
J Transl Med. 2012 Dec 21;10:253
pubmed: 23259758
Cells. 2019 Dec 15;8(12):
pubmed: 31847455
Cell. 2014 Nov 6;159(4):789-99
pubmed: 25417156
Cell. 2014 Mar 27;157(1):121-41
pubmed: 24679531
J Clin Endocrinol Metab. 2014 Dec;99(12):4632-40
pubmed: 25211668
Int J Cancer. 2020 Sep 15;147(6):1535-1547
pubmed: 32068253
Nat Med. 2018 Oct;24(10):1532-1535
pubmed: 30150716
Cells. 2020 Apr 28;9(5):
pubmed: 32354130
mSystems. 2015 Dec 22;1(1):
pubmed: 27822518
J Natl Cancer Inst. 1998 Jun 3;90(11):814-23
pubmed: 9625169
Obes Rev. 2018 Dec;19(12):1719-1734
pubmed: 30144260
J Natl Cancer Inst. 2015 Nov 26;108(4):
pubmed: 26613937
Int J Cancer. 2017 Jun 15;140(12):2667-2677
pubmed: 28295287
Nature. 2016 Jul 06;535(7610):56-64
pubmed: 27383980